Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?

Ramaswamy A, Bhandare M, Bal M, Shrirangwar S, Kataria P, Majumdar S, Swami R, Rohila J, Chaudhari V, Mandavkar S, Chavan N, Shrikhande SV, Ostwal V.

HPB (Oxford). 2019 Aug 9. pii: S1365-182X(19)30620-3. doi: 10.1016/j.hpb.2019.07.006. [Epub ahead of print]

PMID:
31405778
2.

Impact of adjuvant chemotherapy regimen on survival outcomes in immunohistochemical subtypes of ampullary carcinoma.

Al Abbas AI, Falvello V, Zenati M, Mani A, Hogg ME, Zeh HJ 3rd, Singhi A, Bahary N, Zureikat AH.

J Surg Oncol. 2019 Dec 15. doi: 10.1002/jso.25808. [Epub ahead of print]

PMID:
31840257
3.

Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.

Ecker BL, Vollmer CM Jr, Behrman SW, Allegrini V, Aversa J, Ball CG, Barrows CE, Berger AC, Cagigas MN, Christein JD, Dixon E, Fisher WE, Freedman-Weiss M, Guzman-Pruneda F, Hollis RH, House MG, Kent TS, Kowalsky SJ, Malleo G, Salem RR, Salvia R, Schmidt CR, Seykora TF, Zheng R, Zureikat AH, Dickson PV.

JAMA Surg. 2019 May 29. doi: 10.1001/jamasurg.2019.1170. [Epub ahead of print]

PMID:
31141112
4.

Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer.

Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG.

J Surg Oncol. 2012 Mar;105(3):266-72. doi: 10.1002/jso.22090. Epub 2011 Aug 31.

PMID:
21882202
5.

Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy.

Bowitz Lothe IM, Kleive D, Pomianowska E, Cvancarova M, Kure E, Dueland S, Gladhaug IP, Labori KJ.

Pancreatology. 2019 Mar;19(2):316-324. doi: 10.1016/j.pan.2019.01.019. Epub 2019 Jan 25.

PMID:
30713128
6.

Prognostic relevance of lymph node status for patients with ampullary adenocarcinoma after radical resection followed by adjuvant treatment.

Kwon J, Kim K, Chie EK, Kim BH, Jang JY, Kim SW, Oh DY, Bang YJ.

Eur J Surg Oncol. 2017 Sep;43(9):1690-1696. doi: 10.1016/j.ejso.2017.05.024. Epub 2017 Jun 15.

PMID:
28648977
7.

Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma: International Multicenter Cohort Study.

Moekotte AL, Lof S, Van Roessel S, Fontana M, Dreyer S, Shablak A, Casciani F, Mavroeidis VK, Robinson S, Khalil K, Gradinariu G, Mowbray N, Al-Sarireh B, Fusai GK, Roberts K, White S, Soonawalla Z, Jamieson NB, Salvia R, Besselink MG, Abu Hilal M.

Ann Surg. 2019 Jan 7. doi: 10.1097/SLA.0000000000003177. [Epub ahead of print]

PMID:
30628913
8.

Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients.

Baghmar S, Agrawal N, Kumar G, Bihari C, Patidar Y, Kumar S, Chattopadhyay TK, Panda D, Arora A, Pamecha V.

J Gastrointest Cancer. 2019 Sep;50(3):361-369. doi: 10.1007/s12029-018-0058-7.

PMID:
29464529
9.

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer.

JAMA. 2012 Jul 11;308(2):147-56. doi: 10.1001/jama.2012.7352. Erratum in: JAMA. 2012 Nov 14;308(18):1861.

PMID:
22782416
10.

Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma.

Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, Clausen OP, Gladhaug IP.

BMC Cancer. 2008 Jun 11;8:170. doi: 10.1186/1471-2407-8-170.

11.

Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis.

Ecker BL, McMillan MT, Datta J, Mamtani R, Giantonio BJ, Dempsey DT, Fraker DL, Drebin JA, Karakousis GC, Roses RE.

Cancer. 2016 Mar 1;122(5):693-701. doi: 10.1002/cncr.29840. Epub 2015 Dec 30.

12.

Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience.

Al-Jumayli M, Batool A, Middiniti A, Saeed A, Sun W, Al-Rajabi R, Baranda J, Kumer S, Schmitt T, Chidharla A, Kasi A.

J Oncol. 2019 May 2;2019:3293509. doi: 10.1155/2019/3293509. eCollection 2019.

13.

Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.

Hwang JE, Kim H, Shim HJ, Bae WK, Hwang EC, Jeong O, Ryu SY, Park YK, Cho SH, Chung IJ.

J Cancer Res Clin Oncol. 2019 Aug;145(8):2157-2166. doi: 10.1007/s00432-019-02963-7. Epub 2019 Jul 4.

PMID:
31273512
14.

Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.

Okano K, Oshima M, Yachida S, Kushida Y, Kato K, Kamada H, Wato M, Nishihira T, Fukuda Y, Maeba T, Inoue H, Masaki T, Suzuki Y.

J Surg Oncol. 2014 Aug;110(2):156-62. doi: 10.1002/jso.23600. Epub 2014 Mar 12.

PMID:
24619853
15.

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.

Elebro J, Ben Dror L, Heby M, Nodin B, Jirström K, Eberhard J.

Acta Oncol. 2016;55(3):286-96. doi: 10.3109/0284186X.2015.1075663. Epub 2015 Sep 11.

16.

Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?

Westgaard A, Pomianowska E, Clausen OP, Gladhaug IP.

Ann Surg Oncol. 2013 Feb;20(2):430-9. doi: 10.1245/s10434-012-2603-0. Epub 2012 Sep 7.

PMID:
22956064
17.

Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.

Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, Hruban RH, Zhou J, Winter JM, Haddock MG, Donohue JH, Schulick RD, Wolfgang CL, Cameron JL, Herman JM.

Radiat Oncol. 2011 Sep 28;6:126. doi: 10.1186/1748-717X-6-126.

18.

Adjuvant therapy for true ampullary cancer: a systematic review.

Bonet M, Rodrigo A, Vázquez S, Carrizo V, Vilardell F, Mira M.

Clin Transl Oncol. 2020 Jan 11. doi: 10.1007/s12094-019-02278-6. [Epub ahead of print] Review.

PMID:
31927720
19.

Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

You DD, Lee HG, Heo JS, Choi SH, Choi DW.

J Gastrointest Surg. 2009 Sep;13(9):1699-706. doi: 10.1007/s11605-009-0969-5. Epub 2009 Jul 7.

PMID:
19582512
20.

Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.

Perysinakis I, Minaidou E, Leontara V, Mantas D, Sotiropoulos GC, Tsipras H, Zografos GN, Margaris I, Kouraklis G.

Int J Surg Pathol. 2017 Feb;25(1):31-40. doi: 10.1177/1066896916664987. Epub 2016 Aug 20.

PMID:
27543509

Supplemental Content

Support Center